Expression of syndecan-1 in inflammatory bowel disease and a possible mechanism of heparin therapy

Day, Richard, Ilyas, Mohammad, Daszak, Peter, Talbot, Ian and Forbes, Alastair ORCID: (1999) Expression of syndecan-1 in inflammatory bowel disease and a possible mechanism of heparin therapy. Digestive Diseases and Sciences, 44 (12). pp. 2508-15. ISSN 0163-2116

Full text not available from this repository. (Request a copy)


Heparin apparently aids healing in ulcerative colitis although its mechanism of action is unknown. The purpose of this study was to investigate the hypothesis that heparin functions as a coreceptor molecule for basic fibroblast growth factor, a role usually performed by heparan sulfate chains on syndecan-1. A marked reduction of syndecan-1 immunostaining was found in reparative epithelium from inflammatory bowel disease patients. Removal of heparan sulfate on gastrointestinal epithelial cells in vitro reduced the proliferative response to basic fibroblast growth factor. The response to basic fibroblast growth factor was completely restored by the addition of heparin. Loss of syndecan-1 expression occurs in the regenerative mucosa in inflammatory bowel disease. Although this may facilitate tissue motility, its loss probably adversely affects the ability of cells to bind basic fibroblast growth factor. The present data show that heparin may substitute the loss of functional activity of syndecan-1 in the binding of basic fibroblast growth factor.

Item Type: Article
Uncontrolled Keywords: cells, cultured,colitis, ulcerative,crohn disease,epithelial cells,fibroblast growth factor 2,heparin,heparitin sulfate,humans,inflammatory bowel diseases,intestinal mucosa,membrane glycoproteins,proteoglycans,syndecan-1,syndecans,sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User: Pure Connector
Date Deposited: 06 Aug 2014 10:40
Last Modified: 20 Oct 2022 23:58
DOI: 10.1023/A:1026647308089

Actions (login required)

View Item View Item